Analyst firms · Morgan Stanley · NVS

Morgan Stanley NVS price target and rating history

Novartis AG (NVS) · Health Care

Morgan Stanley rates Novartis AG (NVS) Overweight with a $123 price target, as of its latest action on Dec 3, 2025. It has published 5 rating actions on NVS since September 2023, including 3 upgrades and 0 downgrades.

Current rating
Overweight
Price target
$123
Median target, all firms
Too few
Actions on NVS
5

Morgan Stanley price target on NVS

$123$119$11420252026
Morgan Stanley price target on NVS, each point a stated target, January 2024 to August 2025.

Every Morgan Stanley rating on NVS

How other firms rate NVS

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Deutsche BankSellOct 30, 2026
HSBCHoldSep 10, 2026
RBC Capital MarketsSector PerformSep 9, 2026
Argus ResearchBuy$180Mar 11, 2026
CitigroupBuyJan 27, 2026
BarclaysEqual WeightJan 6, 2026
Morgan StanleyOverweightDec 3, 2025
BofA SecuritiesBuyNov 25, 2025

Questions about Morgan Stanley and NVS

What is Morgan Stanley's price target for NVS?
Morgan Stanley's latest stated price target for Novartis AG (NVS) is $123, from its action on Aug 8, 2025.
What is Morgan Stanley's rating on NVS?
Morgan Stanley rates NVS Overweight, a bullish rating, as of Dec 3, 2025.
When did Morgan Stanley last change its view on NVS?
On Dec 3, 2025, Morgan Stanley upgrades to Overweight from Equal-Weight.

More NVS rating histories

All Morgan Stanley ratingsNVS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.